Share

FDA Approves New Treatment for Osteoporosis in Postmenopausal Women at High Risk of Fracture

The U.S. Food and Drug Administration has approved romosozumab-aqqg to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies. The drug will be marketed...
Share

Rise of the Machines: Artificial Intelligence in Healthcare

Artificial intelligence – once only found in a Steven Spielberg movie – is being adopted by the healthcare industry more and more from improving diabetes outcomes to reducing unnecessary thyroid surgeries. As these technologies improve, clinicians will soon have yet another ally to individualize patient care. Artificial intelligence. Machine learning. Those very phrases stir up...
Share

Constructive Disruption in Diabetes

In its inaugural event, the Disrupt Diabetes Design Challenge brought together new perspectives to tackle persistent challenges diabetes with a human-first, design-centric approach. A mechanical engineer is sitting in a conference room at Stanford University. At the table, he is joined by an emergency medicine clinical pharmacist and healthcare designer. Across from them sit two...
Share

Analysis Estimates the Positive Impact of Empagliflozin on Life Expectancy in Adults with Type 2 Diabetes and Established Cardiovascular Disease

Treatment with empagliflozin may positively impact life expectancy in adults with type 2 diabetes and established cardiovascular disease, according to results from the EMPA-REG OUTCOME trial recently published in Circulation. Using actuarial methods and assuming that the demonstrated beneficial effects of empagliflozin remain consistent with long-term use, empagliflozin was estimated to extend life expectancy by one...
Share

Aflibercept Injection Improved Diabetic Retinopathy and Reduced Vision-Threatening Complications in Phase 3 Trial

The Phase 3 PANORAMA trial evaluating aflibercept injection in patients with moderately severe and severe non-proliferative diabetic retinopathy (NPDR) met its one-year (52-week) primary endpoint and key secondary endpoints, the drug’s manufacturer announced today. Regeneron Pharmaceuticals is marketing the drug as EYELA. On the primary endpoint at one year, 80% and 65% of patients receiving...

The endocrine system is a miracle of evolution — a highly complex machine that carries out multiple functions within the body with precision and efficiency. It’s no wonder that as our understanding of the endocrine system advances, the technology we use to study and care for it also becomes more advanced as it approaches the endocrine system in terms of sophistication. Whether that endocrinology technology takes the form of new, advanced medicines, sophisticated imaging and diagnostic technology, or innovative therapies that make life easier for patients, endocrine science continues to push the boundaries and enter new territory. For endocrinologists, staying informed about all of the latest advances in technology and effective treatment options mean better overall care for their patients.

This section compiles the latest news regarding technological advances in endocrinology, featuring articles written for and by the leading voices in endocrine science today. Here, you’ll find articles relating to all the most recent happenings in technology, techniques and general information of interest to endocrinologists. Keeping up with the latest advancements in the field will help you know where medicine has been, where it will advance next, and how it will look in the future. Endocrine News brings you everything you need to know about the future of endocrinology so you’ll know exactly when science catches up to your patients’ needs. The field of endocrinology continues to advance, and Endocrine News is your source for advancing your own knowledge of everything that’s going on for today and tomorrow.